3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
4
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
4
Gynecologic
4
Breast
4
Other hematologic neoplasm
3
Gastrointestinal
3
Genitourinary
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other neoplasm
1
Head & Neck
1
Dermatologic
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Precancerous Conditions
1
Interventions
Oxycodone
2
tremelimumab
1
penpulimab
1
peginterferon alfa-2b
1
Zoledronic Acid
1
Zidovudine
1
Whole-Body Irradiation
1
Valproic Acid
1
Tetradecanoylphorbol Acetate
1
Surveys and Questionnaires
1
Sodium Chloride
1
Selenium
1
Rosuvastatin Calcium
1
Rituximab
1
Ribavirin
1
Radiosurgery
1
Proflavine
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Observation
1
Moxifloxacin
1
Morphine
1
Microarray Analysis
1
Methotrexate
1
Methadone
1
Laser Therapy
1
Interferon alpha-2
1
Infliximab
1
Gene Expression Profiling
1
Gadolinium DTPA
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Microarray Analysis
×
Other neoplasm
×
Clear all
NCT00629577
2017-02-01
SAGE
British Columbia Cancer Agency
Phase 1
Terminated
50 enrolled